Results 101 to 110 of about 16,022 (277)

Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver [PDF]

, 2013
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109769/1/cptclpt201378 ...
Bai, J P F, Brouwer, K L R, Chu, X, Elsby, R, Fenner, K, Galetin, A, Korzekwa, K, Lai, Y, Matsson, P, Moss, A, Nagar, S, Polli, J W, Rosania, G R, Sugiyama, Y   +13 more
core   +2 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

A combined in vitro/in silico approach to identifying off-target receptor toxicity [PDF]

, 2018
Many xenobiotics can bind to off-target receptors and cause toxicity via the dysregulation of downstream transcription factors. Identification of subsequent off-target toxicity in these chemicals has often required extensive chemical testing in animal ...
Colley, H, leedale, J, Mason, C, Murdoch, C, Norton, A, Peeney, D, Sathish, J, Sharkey, K, Sharma, P, Webb, SD   +9 more
core   +4 more sources

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, EarlyView.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict CYP3A-Mediated Drug Interaction between Saxagliptin and Nicardipine: Bridging Rat-to-Human Extrapolation

Pharmaceutics
The aim of this study was to predict the cytochrome P450 3A (CYP3A)-mediated drug–drug interactions (DDIs) between saxagliptin and nicardipine using a physiologically based pharmacokinetic (PBPK) model.
Jeong-Min Lee, Jin-Ha Yoon, Han-Joo Maeng, Yu Chul Kim   +3 more
doaj   +1 more source

Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption

Obesity Reviews, EarlyView.
ABSTRACT Obesity represents a significant threat to global public health, with an estimated 16% of adults worldwide (2022) being classified as people with obesity, with a body mass index of 30 or more. Bariatric surgery is regarded as the most effective treatment option for people with obesity, with the three main types of bariatric surgery being ...
Danielle Wigg, Andrea Edginton, Matthew D. Jones, Nikoletta Fotaki   +3 more
wiley   +1 more source

From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine [PDF]

, 2016
Current computational and mathematical tools are demonstrating the high value of using systems modeling approaches (e.g. Quantitative Systems Pharmacology) to understand the effect of a given compound on the biological and physiological mechanisms ...
Diaz-Zuccarini, V, Pichardo-Almarza, C
core  

Making PBPK models more reproducible in practice

Briefings in Bioinformatics
Abstract Systems biology aims to understand living organisms through mathematically modeling their behaviors at different organizational levels, ranging from molecules to populations. Modeling involves several steps, from determining the model purpose to developing the mathematical model, implementing it computationally, simulating the ...
Elena Domínguez-Romero, Stanislav Mazurenko, Martin Scheringer, Vítor A P Martins dos Santos, Chris T Evelo, Mihail Anton, John M Hancock, Anže Županič, Maria Suarez-Diez   +8 more
openaire   +3 more sources

High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach

Frontiers in Pharmacology
IntroductionThe cytochrome P450 enzyme 3A4 (CYP3A4) mediates numerous drug-drug interactions (DDIs) by inducing the metabolism of co-administered drugs, which can result in reduced therapeutic efficacy or increased toxicity.
Cheng-Guang Yang, Tao Chen, Wen-Teng Si, An-Hai Wang, Hong-Can Ren, Li Wang   +5 more
doaj   +1 more source